Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 8/20 | 0.39 |
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | SIK1 | P57059 | 2/20 | 0.36 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.36 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.36 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22125207 | 0.95 | TTK (0.40) | TTKMAPKAPK5CNR2CNR1SIK1 | |
| SCHEMBL24916596 | 0.93 | TTK (0.38) | TTKMAPKAPK5CNR2CNR1SIK1 | |
| SCHEMBL30349570 | 0.93 | TTK (0.38) | TTKMAPKAPK5CNR2CNR1SIK1 | |
| SCHEMBL24916549 | 0.92 | MAPKAPK5 (0.43) | TTKMAPKAPK5CNR2CNR1SIK1 | |
| SCHEMBL22124708 | 0.91 | TTK (0.41) | TTKMAPKAPK5CNR2CNR1PTK6 | |
| SCHEMBL22124667 | 0.88 | TTK (0.43) | TTKMAPKAPK5PTK6 | |
| SCHEMBL22124700 | 0.87 | PTK6 (0.45) | TTKMAPKAPK5PTK6AURKB | |
| SCHEMBL22124821 | 0.86 | TTK (0.45) | TTKCNR2SIK1SIK2SIK3 | |
| SCHEMBL22123836 | 0.86 | KDR (0.45) | TTKMAPKAPK5CNR2CNR1SIK1 | |
| SCHEMBL22124717 | 0.86 | TTK (0.43) | TTKMAPKAPK5CNR2SIK1SIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | claimed |
| EP-3898630-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| WO-2020126954-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | claimed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3898630-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020126954-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | TTK 4573/4885MAPKAPK5 695/4885CNR2 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.